Snapshot · Russell 3000 · generated 2026-11-11 21:49 UTC

HALO — Halozyme Therapeutics, Inc.

FAIR (MOS +20.9%) · Quality 100/100

Value Score 30 days ago: 44.8 → today 55.9

HALO - Halozyme Therapeutics, Inc.
Data generated 2026-11-11 21:49 UTC (nightly scan, universe: Russell 3000).
Price: 101.68 USD
Intrinsic value: 128.61 USD
Margin of safety: +20.9%
Implied growth (reverse DCF): +13.5% (model assumes +14.0%)
Valuation: FAIR
Value Score: 55.9
Quality: 100/100
Moat score: 88.8 (erosion: none)
FAIR (MOS +20.9%) - Quality 100/100
Source: StocksDeepDive - https://stocksdeepdive.com/s/HALO
Factual information and general commentary only. StocksDeepDive publishes data, model outputs and described calculations from stated inputs. Nothing on this site takes your personal objectives, financial situation or needs into account, and nothing here is financial product advice or a recommendation to buy, hold or sell any security. Model outputs depend entirely on their stated inputs and assumptions. Consider seeking advice from a licensed adviser before acting. Data via Yahoo Finance, Google Trends, StockTwits and NewsAPI; figures may be delayed or revised.

Price

101.68

Intrinsic value

128.61

Margin of safety

+20.9%

Implied growth (reverse DCF)

+13.5%

model assumes +14.0%

Value Score

55.9

Quality

100

Psychology

22.5

Discovery

33.1

price/volume attention only

Moat score

88.8

erosion: none

Value Score: top 20% of Russell 3000 · Quality: top 1%

Open the interactive Deep Dive for HALO →

Use this data programmatically

This page's numbers are also available as JSON at /api/v1/deep-dive/HALO - see the API docs for the full read-only surface, including an MCP server for AI assistants.

Common questions

Is HALO undervalued?

As of 2026-11-11, HALO trades at 101.68 against a computed intrinsic value of 128.61 (+20.9% margin of safety) - StocksDeepDive's valuation label for this is FAIR. This is a described calculation from public data, not a recommendation.

What is Halozyme Therapeutics, Inc.'s Value Score?

Halozyme Therapeutics, Inc.'s Value Score is 55.9 as of 2026-11-11 - it combines value, quality, crowd psychology and market attention into one number.